Loading headlines…

Collected headline brief
Chinese biopharmaceutical firm Akeso announced on Wednesday that its immunotherapy drug had outperformed AstraZeneca’s Imfinzi in a head-to-head phase-three trial for biliary tract cancer. The result represents another breakthrough for…
Complete reading on newsGlobal
Full article · 4 min read
AI-generated editorial illustration / newsGlobal. Not a photograph of an actual event.
Read the full article →Full article · 4 min read
AI-generated editorial illustration / newsGlobal. Not a photograph of an actual event.
Read the full article →Full article · 4 min read
AI-generated editorial illustration / newsGlobal. Not a photograph of an actual event.
Read the full article →There is more to this story